SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to highly polarized community discussions, prominently featuring intense debate around a recent ICE shooting incident in Minneapolis. This focal point of controversy is further amplified by ongoing conversations surrounding various geopolitical strategies, such as those concerning Venezuela's oil sector and the potential acquisition of Greenland, alongside contentious domestic economic policy proposals.

Polygon

Polygon (POL) is generating considerable buzz as its network usage and on-chain revenue surge, fueled by significant token burns and growing institutional adoption from major players. The community expresses strong bullish sentiment, driven by Polygon's pivotal role in scaling Ethereum, key partnerships with global brands, and active discussions surrounding a potential return to the familiar $MATIC ticker.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. ($CRML) is currently trending amidst heightened geopolitical discussions surrounding Greenland and the strategic importance of its rare earth mineral deposits for U.S. national security. The community is buzzing with speculation about potential U.S. government deals, investments in CRML's Tanbreez project, and the possibility of a significant short squeeze, pushing ambitious price targets. This momentum is further amplified by upcoming diplomatic meetings and the company's progress on its Greenland pilot plant, positioning it centrally in the global critical minerals landscape.

WorldFinancial

WLFI is gaining traction amid news of its application for a National Trust Bank Charter to issue the USD1 stablecoin and anticipated launch of a crypto app with real-world asset tokenization initiatives. The community is actively discussing ongoing treasury-funded token buybacks and burns, alongside strategies to acquire tokens at a discount via ALTS, though some caution against potential "pump and dump" dynamics.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending amidst significant market activity following a tragic incident at its Grasberg mine, which has led to operational halts and a revised production outlook. While some investors see this as an immediate challenge, a robust community discussion points to a potential buying opportunity, emphasizing the strong underlying demand for copper from sectors like AI and electrification, with some analysts viewing the stock's reaction as overly pessimistic.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending amidst strong community enthusiasm for its 'AirLock' program, which has seen a substantial portion of the token supply locked up, significantly reducing selling pressure. The community is buzzing about this novel supply control mechanism and recent attention from public figures, reinforcing their vision of AIRCOIN as a revolutionary meme coin poised for broad adoption across exchanges.

Aster is a next-generation decentralized perpetual exchange that combines non-custodial trading with advanced features like hidden orders and multi-chain support. The platform emerged from the merger of Astherus and APX Finance in late 2024, with APX token holders able to migrate their holdings to ASTER.  Aster addresses the gap between centralized and decentralized exchanges by enabling traders to maintain full control of their assets while accessing deep liquidity and CEX-grade trading tools. The platform supports trading of both cryptocurrency perpetuals and U.S. stocks with up to 100x leverage, all settled on-chain in crypto without requiring traditional financial infrastructure.  The platform offers two distinct trading modes to accommodate different user needs. Simple Mode provides one-click, MEV-resistant trading with up to 1001x leverage for beginners, while Pro Mode delivers a full order book with advanced features like automated grid trading and hidden orders that remain invisible until execution.   Aster operates across BNB Chain, Ethereum, Solana, and Arbitrum without requiring bridging, with liquidity pooled across markets to support large trades with minimal slippage. A distinctive feature allows users to deposit yield-generating assets like asBNB or USDF as collateral, earning passive returns while trading, maximizing capital efficiency compared to platforms where collateral sits idle.  Aster received backing from YZi Labs (formerly Binance Labs), which holds a minority stake through a private fund managing over $10 billion on behalf of early Binance executives. Changpeng Zhao, founder of Binance, serves in an advisory role and has personally invested over $2.5 million worth of ASTER tokens.   The ASTER token serves multiple functions including governance rights, staking rewards through liquidity provision, and earning incentives through the platform's points program for traders and liquidity providers.

ASTERION

Aster (ASTER) is actively trending due to significant community discussion surrounding a prominent crypto figure's recent public endorsement and personal purchase, fueling both bullish and skeptical sentiment. Supporters view it as a compelling contender in the perpetual decentralized exchange (DEX) market, anticipating substantial upside. Conversely, critics suggest it may be a manipulated asset, highlighting its competitive landscape and long-term viability within the evolving DEX sector.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending as the community keenly discusses its strategic pivot from traditional Bitcoin mining to a significant AI infrastructure provider. A new AI infrastructure partnership with Anthropic and Fluidstack, including a $7 billion data center lease backed by Google, is fueling conversations about its strong growth trajectory. Investors are closely watching its performance against other crypto and AI plays, seeing it as a key beneficiary of the expanding AI sector.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending sharply after exceeding uranium production targets and advancing its significant Vara Mada rare-earth project, positioning itself as a critical player in U.S. energy and material security. The community is buzzing about the company's long-term contracts and the Department of Energy's funding boost for domestic uranium, signaling strong government backing. Despite some valuation debates, many view UUUU as a foundational investment for the nuclear energy revival and the growing demand for rare earths in advanced technologies.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as the community intensely debates the impact of Novo Nordisk's oral GLP-1 pill becoming widely available via Amazon Pharmacy, seen as a major competitive threat. This development, alongside recent analyst downgrades and regulatory scrutiny on compounded GLP-1s, has driven significant bearish sentiment, though bulls emphasize the company's diversified growth initiatives and long-term vision.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...

Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB

Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Inc. (INMB) on Monday said that its experimental drug XPro did not show any effects in the intent-to-treat population in a mid-stage study evaluating its effectiveness in early Alzheimer’s Disease (AD) with biomarkers of inflammation.INmune’s stock fell about 59% in morning trade at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107380/0/en/INmune-Bio-Reports-Key-Findings-from-Phase-2-MINDFuL-Trial-of-XPro-in-Early-Alzheimer-s-Disease.html">trial </a>enrolled 208 participants with early-stage Alzheimer’s to asses the drug’s potential in slowing cognitive decline by tackling neuroinflammation.The primary endpoint of the study was a change in cognition over 6 months on the Early Mild Alzheimer’s Cognitive Composite (EMACC). EMACC is a tool used in clinical trials and research to assess cognitive changes in individuals with early or mild Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).The primary endpoint was not met in the intent-to-treat population.However, changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of 100 early Alzheimer's patients with inflammation biomarkers who were treated with XPro, compared to patients treated with placebo, the company said.CEO RJ Tesi said that the findings lay the foundation for advancing XPro as a “promising treatment option” for Alzheimer’s.XPro treatment was safe and well-tolerated, the company added.<a href="https://stocktwits.com/symbol/INMB">INmune</a> now intends to schedule an end-of-mid-stage meeting with the U.S. Food and Drug Administration (FDA) in the last quarter of 2025 to define the path forward for a pivotal trial to support XPro approval in early Alzheimer’s.Despite the drop in INMune stock during Monday’s trading session, retail sentiment around the stock is trending in the ‘extremely bullish’ territory on Stocktwits.INMB stock is down by about 53% this year and by about 74% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-flu-vaccine-show-positive-results-in-late-stage-trial/chmZitPRR72">Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

Equity

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

Investing.com --  INmune Bio  Inc. (NASDAQ:INMB) stock fell 60% in pre-market trading Monday after the company reported mixed results from its Phase 2 MINDFuL trial of XPro in early Alzheimer’s disease patients.

INmune Bio Inc. (INMB) on Friday said that it entered into securities purchase agreements with two healthcare-focused institutional investors for the purchase and sale of 3 million shares of its common stock.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html">said</a> that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share. The proceeds from the offering are expected to be about $19 million, excluding costs such as fees to the placement agency Alliance Global Partners.<a href="https://stocktwits.com/symbol/INMB">INmune Bio</a> said that it intends to use the proceeds from the offering for working capital purposes and general corporate purposes.The closing of the offering is expected to occur on or about June 20.INMB shares are down 19% on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around INmune Bio is unmoved within the ‘extremely bullish’ territory over the past 24 hours, while retail chatter stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_2_24_21_PM_png_cb3ab03d42.webp" alt="INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>INMB's Sentiment Meter and Message Volume as of 2:25 p.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the company is headed to a year-long downtrend.<stembedurl>https://stocktwits.com/CharlesIV/message/619287462</stembedurl>Another user opined that a stock offering before data results is “sketchy.”<stembedurl>https://stocktwits.com/EddieGon/message/619286742</stembedurl>INmune Bio is slated to present topline results from its mid-stage Alzheimer’s trial, the MINDFuL study, on Monday. The trial is testing its lead drug candidate XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation.The MINDFuL study will compare XProTM to placebo to find out whether XPro affects memory, functioning, and behavior. The study will also evaluate whether XPro is safe and tolerable.INMB stock is up by 9% this year and down by about 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-stock-rises-on-us-supreme-court-ruling-in-favor-of-health-insurers-covering-preventive-care/chmWPN2RRe5">Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Stock Slumps On 3M Share Offering Ahead Of Mid-stage Trial Data, But Retail Remains Bullish 

The company said that it would sell 3 million shares of its common stock in a registered direct offering at a purchase price of $6.30 per share.

INmune Bio saw its stock surge 75% in after-hours trading Thursday after disclosing plans to unveil topline results from its Phase 2 Alzheimer’s trial on Monday.The company will present findings from its MINDFuL study, a placebo-controlled trial testing its lead drug candidate XPro in patients showing early signs of Alzheimer’s.&nbsp;The study participants consisted of 208 patients diagnosed with mild cognitive impairment or mild Alzheimer's disease.&nbsp;The average age of the participants was 72 years. In all of the participants, biomarkers of inflammation were present.&nbsp;The inflammatory biomarkers observed were elevated C-reactive protein levels, along with increased ESR and higher HbA1c values and genetic markers such as the APOE ε4 allele.&nbsp;Participants were randomized 2-to-1 to receive weekly doses of XPro or a placebo for just under six months.The main goal of the study is to assess cognitive change using a custom measurement tool called the early and mild Alzheimer's cognitive composite&nbsp;(EMACC), designed to detect subtle shifts in early-stage Alzheimer’s.&nbsp;Previous data showed the EMACC aligns well with other standard assessments like MMSE and CDR-SB.The company reported that over two-thirds of participants carried the APOE ε4 gene, and nearly two-thirds qualified through more than one biomarker.&nbsp;Roughly 72% of patients screened for the trial were not enrolled, mostly due to more advanced disease.In addition to cognitive scoring, the study includes secondary measures such as evaluations of daily living, neuropsychiatric symptoms, and biological markers.XPro is part of the company’s broader immune-targeting drug platform, which focuses on conditions believed to stem from chronic inflammation.&nbsp;<a href="https://stocktwits.com/symbol/INMB">INmune</a> is also exploring XPro for use in depression, alongside other programs for cancer and rare skin disorders.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 344% surge in 24-hour message volume.One user said that the timing of the announcement indicated confidence from the company, noting that results slated for early Monday were unlikely to disappoint.<stembedurl>https://stocktwits.com/winefan/message/619189685</stembedurl>They also referenced commentary from&nbsp;“pharma bro”&nbsp;Martin&nbsp;Shkreli, who previously stated that if the drug proves effective, the stock could surge dramatically, possibly even reaching triple-digit levels.Another user noted the pre-market Monday scheduling as a potentially encouraging signal but said they wouldn’t celebrate until the actual data is released.<stembedurl>https://stocktwits.com/BoilerKing/message/619167991</stembedurl>The stock has risen 27.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week

INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders.

<ul><li>Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma</li><li>Small Biotech Companies Lead the Charge with Disruptive Approaches to Treating Alzheimer’s</li></ul>Alzheimer’s disease has been one of the most challenging conditions for the pharmaceutical industry to address. While companies like&nbsp;Biogen (BIIB) and&nbsp;Eli Lilly (LLY) have made notable strides with drugs like&nbsp;Aduhelm and&nbsp;Donanemab, which target amyloid plaques, breakthrough treatments that offer substantial cognitive improvements remain elusive. Despite these advancements, many of these drugs focus on slowing disease progression rather than providing a cure, and their impact has been limited.Historically, much of the innovation in Alzheimer’s research has come from smaller biotech companies, many of which are eventually acquired by larger pharmaceutical firms like BIIB and LLY. However, the results from these acquisitions have often not met expectations, leaving room for new players to disrupt the market with more innovative approaches.For investors looking for broader exposure to the biotech sector, the&nbsp;XBI ETF (SPDR S&amp;P Biotech ETF) offers a more diversified way to play the space. XBI tracks an equal-weighted index of U.S. biotech stocks, providing exposure to both large players like Biogen and smaller upstarts working on novel treatments. The ETF has seen strong performance recently, driven by optimism around biotech innovation in areas like Alzheimer’s, oncology, and rare diseases. While individual biotech stocks can be volatile, XBI spreads the risk across a broader portfolio, making it a compelling option for those looking to invest in the sector without taking on the higher risk of single-stock picks.The Alzheimer’s drug market is projected to reach $13.7 billion by 2029, and despite the presence of big pharma, there remains a significant opportunity for companies with novel therapies to address this unmet need. In this article, we examine three small-cap biotech players —&nbsp;Cassava Sciences (SAVA),&nbsp;INmune Bio (INMB), and&nbsp;Annovis Bio (ANVS) — that are working on breakthrough Alzheimer’s therapies. We will break down their potential by analyzing the good, the bad, the ugly, and their overall investability.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Cassava Sciences (SAVA)&nbsp;<a href="https://stocktwits.com/symbol/SAVA">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Cassava Sciences is developing Simufilam, a drug that targets a unique protein misfolding pathway in Alzheimer’s disease. Unlike traditional therapies that focus solely on amyloid plaques, Simufilam aims to correct the shape of the protein Filamin A, which may influence multiple Alzheimer’s disease processes. This innovative approach could potentially address multiple aspects of the disease.Cassava has faced a mix of positive and negative news. Its Phase 2 trial results showed cognitive improvement in Alzheimer’s patients, generating optimism. However, allegations of data manipulation have cast a cloud over the company’s achievements, leading to regulatory scrutiny and volatility in the stock.<h4>The Good:</h4>Simufilam’s unique approach could disrupt the Alzheimer’s drug market if Phase 3 trials confirm its efficacy. With Alzheimer’s treatments falling short of significant impact, a drug that improves cognitive function would undoubtedly capture massive attention. Additionally, Cassava’s high short interest could lead to a short squeeze if positive news emerges, providing an opportunity for investors to capitalize on sharp price movements. Notably, if the drug succeeds, the company’s stock could skyrocket, presenting massive upside potential for investors.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_27_24_AM_67dc564cb2.png" alt="Screenshot 2024-10-03 at 11.27.24 AM.png"><h4>The Bad:</h4>The allegations of data manipulation have raised questions about the integrity of Cassava’s research. Although the company has denied wrongdoing, the concerns could weigh heavily on investor confidence until the Phase 3 data is released. Moreover, Alzheimer’s disease is notoriously difficult to treat, and even promising drugs can fail in late-stage trials.<h4>The Ugly:</h4>Cassava’s main challenge is that it’s a one-trick pony. The company’s future is almost entirely dependent on the success of Simufilam. If the Phase 3 trials show negative results, the stock could plummet, potentially wiping out investors. Cassava lacks diversification in its pipeline, and failure could be disastrous for the company’s long-term viability.<h4>Investability:</h4>Cassava Sciences is a high-risk, high-reward stock. For investors willing to take on significant risk, the potential upside of Simufilam is enormous. However, given the controversies surrounding the company, a cautious approach is warranted. Those looking for long-term gains should monitor the Phase 3 results closely before making any major investments.&nbsp;<h3>INmune Bio (INMB)&nbsp; <a href="https://stocktwits.com/symbol/inmb">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>INmune Bio is taking a unique approach to treating Alzheimer’s by focusing on neuroinflammation rather than the traditional amyloid or tau pathways. The company’s lead drug, XPro1595, is designed to reduce brain inflammation by neutralizing soluble TNF (sTNF), a cytokine that drives chronic inflammation in Alzheimer’s patients. This could potentially offer a complementary treatment to existing therapies. In addition to its Alzheimer’s focus, INmune Bio has a strong oncology portfolio, which includes its INKmune platform aimed at improving cancer immunotherapy.Recent clinical data on XPro1595 has been promising, with the drug showing efficacy in reducing neuroinflammation. The company is preparing for larger trials in 2025, which could solidify its position in the Alzheimer’s space.<h4>The Good:</h4>INmune Bio’s focus on neuroinflammation sets it apart from other Alzheimer’s treatments. Reducing inflammation has shown to be a crucial factor in preventing cognitive decline, and XPro1595’s early data suggests it could be a game-changer in this area. Furthermore, INmune Bio’s diversified portfolio, including its oncology platform, gives it additional avenues for growth beyond Alzheimer’s, reducing its risk compared to Cassava Sciences.<h4>The Bad:</h4>Despite the promise of XPro1595, the drug is still in early-stage trials, and it could take years before it reaches the market. The road to FDA approval is long and fraught with challenges, and investors will need to be patient as the company moves through its clinical development phases.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_28_27_AM_bf6e45fe54.png" alt="Screenshot 2024-10-03 at 11.28.27 AM.png"><h4>The Ugly:</h4>One of the biggest risks for INmune Bio is its reliance on early-stage data. While XPro1595 has shown promise, it has not yet demonstrated long-term efficacy in larger trials. Any setbacks in the trial process could delay the drug’s development and hurt the company’s stock.<h4>Investability:</h4>INmune Bio offers the best reward-to-risk ratio among the three companies. With a diversified portfolio and a promising Alzheimer’s treatment, INmune Bio is well-positioned to capitalize on breakthroughs in both neuroinflammation and oncology. Investors looking for a biotech stock with high upside potential but less concentrated risk compared to Cassava Sciences may find INmune Bio to be a compelling option.<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;<h3>Annovis Bio (ANVS)&nbsp;&nbsp;<a href="https://stocktwits.com/symbol/ANVS">[Follow on Stocktwits.com]</a></h3><h4>The Lowdown:</h4>Annovis Bio is targeting Alzheimer’s with Buntanetap, a drug that aims to reduce multiple neurotoxic proteins, including amyloid, tau, and alpha-synuclein. By taking a multi-pronged approach, Annovis hopes to provide a more comprehensive treatment for neurodegenerative diseases like Alzheimer’s and Parkinson’s.The company recently reported positive early-stage trial results, showing that Buntanetap improved cognition in patients with Alzheimer’s. With a Phase 2 trial in progress, Annovis Bio is positioning itself as a serious contender in the Alzheimer’s space.<h4>The Good:</h4>Buntanetap’s ability to target multiple neurotoxic proteins gives it an advantage over single-target therapies. The early data showing cognitive improvement has bolstered investor confidence, and the drug’s potential to address both Alzheimer’s and Parkinson’s opens up additional market opportunities. If Buntanetap continues to perform well in clinical trials, Annovis Bio could see substantial growth.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_03_at_11_29_39_AM_fafa150775.png" alt="Screenshot 2024-10-03 at 11.29.39 AM.png"><h4>The Bad:</h4>However, Annovis Bio is still in the early stages of its clinical trials, and the road to commercialization is long. The company will need to demonstrate consistent efficacy in larger trials before it can become a serious player in the Alzheimer’s market. Additionally, competition from other multi-target therapies could limit its market share.<h4>The Ugly:</h4>Like many small biotech companies, Annovis Bio is reliant on the success of a single drug candidate. If Buntanetap fails in its clinical trials, the company could struggle to recover. Investors should be aware of the high risk associated with this stock.<h4>Investability:</h4>Annovis Bio presents a speculative but potentially rewarding investment. The company’s multi-target approach could offer greater efficacy than traditional Alzheimer’s treatments, but it remains a high-risk bet. Investors should monitor the progress of its clinical trials closely before making any significant investments.<h3>Conclusion</h3>The Alzheimer’s drug market is poised for disruption, and companies like Cassava Sciences, INmune Bio, and Annovis Bio are leading the charge with innovative treatments. While these stocks come with substantial risks, the potential rewards could be life-changing — both for patients and investors. For those willing to take a gamble on the future of Alzheimer’s treatment, these companies offer a unique opportunity to not only achieve significant financial gains but also to contribute to a cause that could improve millions of lives.Of the three, INmune Bio stands out for its diversified portfolio and promising early data, making it a potentially safer bet. Cassava Sciences offers the most dramatic upside but comes with higher risks due to its single-drug focus. Annovis Bio, while speculative, offers intriguing potential with its multi-targeted approach.As always, investors should weigh the risks and rewards carefully but know that their investments could make a profound difference in the fight against one of the most challenging diseases of our time.&nbsp;<h4>Read Now:&nbsp;<a href="https://wealthyvc.com/featured/20m-healthcare-stock-breaks-out-after-rising-1700-on-medicare-and-medicaid-clearance-heres-whats-being-announced-in-the-coming-months-in-a-25x-larger-market/">This $20m Company Soars 1,700% on Medicare &amp; Medicaid Clearance— Find out What’s Being Announced in the Coming Months in a Market 25X Larger</a></h4>&nbsp;This author or the principals of WVC do not hold any of the stocks mentioned in this article.&nbsp;<ul><li><a href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;</li><li><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a></li><li>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.com</li></ul>

Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Discover how small-cap biotech companies like Cassava Sciences, INmune Bio, and Annovis Bio are shaking up the $13.7 billion Alzheimer’s drug market with innovative treatments. Explore their potential for high-risk, high-reward gains

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting groundbreaking therapies, high-risk, high-reward investments lie ahead.


INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

INmune Bio Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

INMB
INmune Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INMB News

INMBINmune Bio Inc